Marshall Wace, LLP Cytom X Therapeutics, Inc. Transaction History

Marshall Wace, LLP

$74.4 Billion
Q1 2025

A detailed history of Marshall Wace, LLP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 85,539 shares of CTMX stock, worth $199,305. This represents 0.0% of its overall portfolio holdings.

Number of Shares

85,539

Holding current value

$199,305

% of portfolio

0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$0.58 - $1.14 $49,612 - $97,514	85,539 New	85,539 $54,000
Q1 2024 May 15, 2024	SELL	$1.41 - $2.74 $438,491 - $852,104	-310,987 Reduced 85.61%	52,289 $113,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $1.55 $15,319 - $22,191	-14,317 Reduced 3.79%	363,276 $563,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $1.87 $374,104 - $555,217	-296,908 Reduced 44.02%	377,593 $487,000
Q2 2023 Aug 14, 2023	SELL	$1.41 - $1.92 $78,166 - $106,439	-55,437 Reduced 7.59%	674,501 $1.16 Million
Q1 2023 May 15, 2023	BUY	$1.48 - $2.88 $1.08 Million - $2.1 Million	729,938 New	729,938 $1.1 Million
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $29,671 - $47,522	-24,123 Reduced 37.61%	40,021 $58,000
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $74,783 - $141,257	48,878 Added 320.18%	64,144 $118,000
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $40,760 - $71,444	15,266 New	15,266 $40,000
Q2 2020 Aug 13, 2020	SELL	$7.4 - $14.64 $868,708 - $1.72 Million	-117,393 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$3.61 - $8.6 $1.03 Million - $2.44 Million	-284,033 Reduced 70.76%	117,393 $900,000
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $2.03 Million - $3.51 Million	393,401 Added 4902.19%	401,426 $3.34 Million
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $59,224 - $98,306	8,025 New	8,025 $59,000
Q1 2019 May 14, 2019	SELL	$9.5 - $19.16 $492,822 - $993,944	-51,876 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $362,071 - $530,980	-28,532 Reduced 35.48%	51,876 $783,000
Q3 2018 Nov 14, 2018	BUY	$18.04 - $26.41 $1.45 Million - $2.12 Million	80,408 New	80,408 $1.49 Million
Q2 2018 Aug 14, 2018	SELL	$21.38 - $29.68 $258,698 - $359,128	-12,100 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$21.76 - $34.22 $263,296 - $414,062	12,100 New	12,100 $344,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

44.1M

Call Options Held

8.9K

Put Options Held

47.9K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $154M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account